Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Understanding thrombin and hemostasis

J W Fenton1, F A Ofosu, D V Brezniak

  • 1New York State Department of Health, Wadsworth Center for Laboratories and Research, Albany.

Hematology/Oncology Clinics of North America
|December 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The fraction of recombinant factor VIII:Ag unable to bind von Willebrand factor has no FVIII coagulant activity: studies in vitro.

Haemophilia : the official journal of the World Federation of Hemophilia·2012
Same author

Management of bleeding disorders: basic science.

Haemophilia : the official journal of the World Federation of Hemophilia·2012
Same author

Understanding FVIII/VWF complex--report from a symposium of XXIX WFH meeting 2010.

Haemophilia : the official journal of the World Federation of Hemophilia·2011
Same author

Recommendations on biosimilar low-molecular-weight heparins.

Journal of thrombosis and haemostasis : JTH·2009
Same author

Hypercoagulability after trauma: hemostatic changes and relationship to venous thromboembolism.

Thrombosis research·2008
Same author

Statins and thrombin.

Current drug targets. Cardiovascular & haematological disorders·2005
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

Thrombin plays diverse roles in hemostasis, from clot formation to wound healing. Small molecule inhibitors can target thrombin within clots, but caution is advised due to thrombin's beneficial roles in healing.

Area of Science:

  • Biochemistry
  • Hematology
  • Physiology

Background:

  • Thrombin is a key enzyme in blood coagulation and fibrinolysis with multifaceted roles.
  • Its generation and activity are tightly regulated to balance hemostasis and prevent thrombosis.
  • Thrombin exhibits functions beyond coagulation, including roles in wound healing.

Purpose of the Study:

  • To explore the diverse functions of thrombin in hemostasis, from injury to recovery.
  • To investigate the mechanisms of thrombin generation, inactivation, and its incorporation into thrombi.
  • To evaluate the potential of small molecule thrombin inhibitors in managing thrombosis and their implications for wound healing.

Main Methods:

  • Review of existing literature on thrombin's role in coagulation and fibrinolysis.

Related Experiment Videos

  • Analysis of thrombin's interaction with inhibitors and its incorporation into thrombi.
  • Discussion of the structural features of thrombin enabling inhibitor design.

    • Main Results:

    • Thrombin possesses multiple functions in hemostasis, unlike other coagulation factors.
    • Alpha-thrombin converts fibrinogen to fibrin and is incorporated into thrombi, where it is protected.
    • Small inhibitors can penetrate thrombi, unlike larger ones, offering potential for rethrombosis prevention.
    • Low thrombin levels are implicated in promoting wound healing.

    Conclusions:

    • Thrombin's unique properties necessitate careful consideration for therapeutic interventions.
    • Small molecule inhibitors offer a promising strategy for managing thrombosis by targeting thrombin within clots.
    • Balancing antithrombotic therapy with the pro-healing functions of thrombin is crucial for optimal patient outcomes.